This study explores the effectiveness of RP-1664, a selective oral inhibitor of polo-like kinase 4 (PLK4), targeting adult and adolescent patients with TRIM37-high solid tumors.

Theratechnologies Inc. has achieved a significant milestone in its Phase 1 clinical trial for sudocetaxel zendusortide.

Neurophth Therapeutics has successfully enrolled the final participant in its Phase I/II clinical study of Opvika® (Esonadogene Imvoparvovec), a treatment for Leber hereditary optic neuropathy (LHON) caused by the ND4 gene mutation.

Tharimmune, Inc. has successfully completed a Phase 1 clinical trial for TH104, a transmucosal buccal film containing nalmefene, which is well-tolerated with mild side effects.

May 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., together with Alvotech, have declared the launch of SIMLANDI (adalimumab-ryvk) injection within the United States.

Arrowhead Pharmaceuticals Unveils New Clinical Data Indicating Significant Gene Knockdown by ARO-RAGE in Asthma Patients.

Nature Communications Releases Key Data Showing Effectiveness and Safety of CSL and Arcturus Therapeutics’ COVID-19 Vaccine.

Atara Biotherapeutics Files Biologics License Application for Tab-cel® to Treat EBV Positive Post-Transplant Lymphoproliferative Disease with the FDA.

New Phase 2a trial data shows Endeavor BioMedicinesa’ ENV-101 enhanced lung performance and reversed critical indicators of lung fibrosis in idiopathic pulmonary fibrosis patients.

Experimental Seladelpar Shows Notable Advancements in Liver Disease and Alleviates Itching in Primary Biliary Cholangitis.

The SUPERNOVA Phase III trial for the long-acting antibody sipavibart successfully met its primary goals in preventing COVID-19 among immunocompromised patients.